A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target of no less than EUR 4.90 for Vidac Pharma, representing a potential upside of 1,662% from the current price level of EUR 0.278.
News & Events